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Abstract
Background: Increasing evidence has shown that microRNAs function as oncogenes or tumor suppressors in
human malignancies, but the roles of miR-186 in human bladder cancer (BC) is still unclear.
Methods: First, quantitative real-time PCR (qRT-PCR) was performed to detect miR-186 expression in bladder cancer
tissues and cell lines. Then, Bioinformatics analysis, combined with luciferase reporter assay demonstrated the
target gene of miR-186. Finally, the roles of miR-186 in regulation of tumor proliferation and invasion were
further investigated.
Results: Here, our study showed miR-186 was down-regulated in bladder cancer tissues and cell lines.
Luciferase reporter assay showed that miR-186 targets NSBP1 3′-untranslated region (UTR) directly and
suppresses NSBP1 (HMGN5) expression in human bladder cancer cells. NSBP1 siRNA- and miR-186-mediated
NSBP1 knock-down experiments revealed that miR-186 suppresses cell proliferation and invasion through
suppression of NSBP1 expression. Expression analysis of a set of epithelial-mesenchymal transition (EMT)
markers showed that NSBP1 involves miR-186 suppressed EMT which reducing the expression of mesenchymal
markers (vimentin and N-cadherin) and inducing the expression of epithelial marker (E-cadherin).
Conclusions: Our data first time identified miR-186 as the upstream regulator of NSBP1 and also suggest miR-186-
suppressed NSBP1 as a novel therapeutic approach for bladder cancer.
Background
Bladder cancer is the most common malignancy involv-
ing the urinary system with more than 350,000 new
cases diagnosed globally each year [1, 2]. Bladder cancer
is the fourth most common cancer in males and ninth
most common in females, and is by far the most
frequent urological malignancy in China [3]. Despite
significant advances in accurate and effective diagnostic
and therapeutic methods, bladder cancer remains a
highly prevalent and lethal malignancy [4]. Therefore, it
is urgent for novel treatment strategies based on new
molecular networks to improve the poor prognosis in
patients with bladder cancer.
High mobility group N (HMGN) proteins are a family
of ubiquitous nuclear proteins which modify the struc-
ture of chromatin to attain a conformation that
facilitates and enhances transcription, histone modifica-
tions, replication and repair [5, 6]. NSBP1 (Nucleosomal
Binding Protein 1), also named HMGN5, is a new mem-
ber of the HMGN protein family, is reported to bind to
the nucleosomes via nucleosomal binding domain
(NBD), unfold chromatin, and modulate gene transcrip-
tion [7]. Accumulating studies showed that NSBP1 was
abundantly expressed in various types of cancer, includ-
ing gliomas [8], clear cell renal cell carcinoma [9] and
prostate cancer [10]. Recently, Wahafu et al. revealed
that NSBP1 is highly expressed in human bladder cancer
and promotes the proliferation and invasion of bladder
cancer cells [11]. However, it is not known whether
NSBP1 expression is regulated by specific miRNAs in
bladder cancer.
MicroRNA (miRNA), an abundant group of endogen-
ous non-coding single strand RNAs of 22 nucleotides,
participate in the regulation of a range of biological pro-
cesses including cell proliferation, apoptosis, invasion,
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migration, differentiation, by regulating the expression
of genes at post-transcriptional level [12–15]. Increasing
evidence indicates that the miRNAs, function as either
oncogenes or tumor suppressors, are aberrantly
expressed and contribute to cancer progression as a
result of changes in expression of their target genes in
various cancers such as breast cancer, lung cancer, pan-
creatic cancer and nasopharyngeal carcinoma [16–21].
Accumulating studies showed that the deregulated
expression of miR-186 was observed in various cancers.
For example, miR-186 was reported to be significantly
upregulated in most pancreatic cancer [22]. Recently,
miR-186 function as a tumor suppressive miRNA and
miR-186 expression level is down-regulated in various
human malignancies: endometrial cancer [23], prostate
cancer [24], medulloblastomas [25], non-small cell lung
carcinoma [26, 27]. However, the expression and mech-
anism of miR-186 in bladder cancer remain unclear.
In this study, we detected that miR‑186 is signifi-
cantly downregulated in bladder cancer cell lines.
NSBP1 is a direct target of miR-186 and the overex-
pression of miR-186 suppresses cell proliferation and
invasion of bladder cancer through suppression of
NSBP1 expression and EMT.
Methods
Human tissue specimens
Twenty clinical BC tissues and their corresponding
noncancerous bladder tissues used in this study were
obtained from The Third Xiangya Hospital (Changsha,
China) after surgical resection. All samples were im-
mediately snapped frozen in liquid nitrogen and
stored at −80 °C until RNA extraction. Informed con-
sents were obtained from each patient to approve the
use of their tissues for research purposes. The study
protocol was approved by the Institute Research
Ethics Committee at Central South University.
Cell culture and transfection
The human bladder cancer cell lines (J82, HT1376,
RT4, T24 and TCCSUP) and immortalized human
bladder epithelium (HCV29) cells were cultured in
DMEM (Invitrogen) supplemented with 10 % FCS at
37 °C in 5 % CO2 cell culture incubator. miR-186
mimics and scramble control mimics (GenePharma,
Suzhou, China) were transfected in J82 cells at a final
concentration of 50 nM using Lipofectamine 2000
reagent (Invitrogen).
qRT-PCR
Total RNA was isolated from tissues and cell lines using
the miRNeasy Mini Kit (Qiagen). The miRNA Q-PCR
Detection Kit (GeneCopoeia) was used for quantification
of miRNA levels according to the manufacturer’s
protocol. The protocol was conducted for 35 cycles at
95 °C for 3 min, 95 °C for 12 s, and 58 °C for 30 s. The
PCR amplification for the quantification of the miR-186
and U6 was performed using TaqMan miRNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA,
USA) and TaqMan Human MiRNA Assay Kit (Applied
Biosystems, Foster City, CA, USA). The relative expres-
sion of miR-186 was shown as fold difference relative to
U6. The PCR amplification for the quantification of the
NSBP1 and GAPDH mRNAs was performed using an
ABI PRISM 7300 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) and a SYBR®Premix
Ex Taq™ ii (Perfect Real Time) Kit (Takara Bio, Shiga,
Japan). The primers were as follows: miR-186: 5′-
GCGGCGCAAAGAATTCTCCT-3′; miR-186 mimics,
forward primer: 5′-GCGGCGCAAAGAATTCTCCT-3′
and reverse primer: 5′-GTGCAGGGTCCGAGGT-3′;
NSBP1, forward primer: 5′-TCGGCTTTTTTTCTGCT
GACTAA-3 and reverse primer: 5′-CTCTTTGGCT
CCTGCCTCAT-3′. β-actin, forward primer: 5′- CATT
AAGGAGAAGCTGTGCT-3′ and reverse primer: 5′-
GTTGAAGGTAGTTTCGTGGA -3′.
Western blot
Whole cell extracts were prepared with a cell lysis re-
agent (Sigma-Aldrich, St. Louis, MO, USA) according to
the manual, and then, the protein was quantified by a
BCA assay (Pierce, Rockford, IL, USA). Then, the pro-
tein samples were separated by SDS-PAGE (10 %) and
detected by Western blot using polyclonal (rabbit) anti-
NSBP1, anti-E-cadherin, anti-N-cadherin and anti-
Vimentin antibody (Santa Cruz Bio-technology, Santa
Cruz, CA, USA). Goat anti-rabbit IgG (Pierce, Rockford,
IL, USA) secondary antibody conjugated to horseradish
peroxidase and ECL detection systems (SuperSignal
West Femto, Pierce) were used for detection.
Luciferase reporter assay
The 3′-UTR sequence of NSBP1 was amplified from
normal human genomic DNA and subcloned into the
pmirGLO luciferase reporter vector (Promega). HEK
293 T cells (3.5 × 10 4) were seeded in triplicate in 24-
well plates and cotransfected with wild-type (WT) or
mutant (Mut) 3′-UTR vectors and miR-186 mimics
using Lipofectamine 2000. After 48 h, the cells were
assayed for luciferase activity using the Dual-Luciferase
Reporter Assay System (Promega) by following the man-
ufacturer’s instructions. The firefly luciferase activities
were normalized to Renilla luciferase activity. The firefly
luciferase activity of the cells that were transfected with
miRNA mimics or inhibitors is represented as the per-
centage of activity relative to that of cells that were
transfected with negative controls. All experiments were
performed in triplicate.
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Cell proliferation assay and invasion assay
The 3-(4,5-dimethylthiazal-2-yl)-2,5-diphenyl-tetrazolium
bromide (MTT) assay was used to estimate cell viability
[28]. Briefly, cells were plated at a density of 1 × 10 4 cells
per well in 96-well plates. After exposure to specific treat-
ment, the cells were incubated with MTT at a final con-
centration of 0.5 mg/ml for 4 h at 37 °C. After the
removal of the medium, 150 mM DMSO solutions were
added to dissolve the formazan crystals. The absorbance
was read at 570 nm using a multi-well scanning spectro-
photometer reader. Cells in the control group were
considered 100 % viable.
The capability of cell invasion was examined by trans-
well invasion assay. Cells were cultivated to 80 % conflu-
ence on the 12-well plates. Then, we observed the
procedures of cellular growth at 72 h. All the experi-
ments were repeated in triplicate. The transwell migra-
tion chambers were used to evaluate cell invasion. Then
invasing cells across the membrane were counted under
a light microscope.
Statistical analysis
Each experiment was repeated at least three times.
Data were shown as mean ± s.d and analyzed using
SPSS 18.0. Statistical comparisons between groups
were analyzed using correlation between expression
levels of miR-186 and its target genes in BC tissues
was analyzed using Spearman’s correlation coefficient.
Student’s t-test and a two-tailed p < 0.05 were consid-
ered to indicate statistical significance.
Results
The expression of miR-186 and NSBP1 in BC tissues and
cell lines
Recently, miR-186 function as a tumor suppressive
miRNA and miR-186 expression level is down-
regulated in various human malignancies [26, 27].
However, the expression and mechanism of miR-186
in bladder cancer remain unclear. Here, we analyzed
the miR-186 expression in 20 paired clinical BC and
adjacent noncancerous bladder tissues using qRT-
PCR. We found that miR-186 expression was signifi-
cantly decreased in BC tissues relative to the matched
non-tumor tissues (P < 0.05, Fig. 1a). Moreover, our
data indicated that there was an inverse correlation
between miR-186 and NSBP1 expression (Fig. 1b).
Next, we employed qRT-PCR to detect miR-186 levels
in human bladder cancer cell lines (J82, HT1376, RT4,
T24 and TCCSUP) and immortalized human bladder
epithelium (HCV29) cells. The miR-186 expression was
downregulated in all bladder cancer cell lines as com-
pared with that in HCV29 (Fig. 1c). These data indicates
that miR-186 may function as tumor suppressor in blad-
der cancer cells.
We next assayed the NSBP1 expression levels in hu-
man bladder cancer cell lines (J82, HT1376, RT4, T24
Fig. 1 The expression of miR-186 and NSBP1 in bladder cancer tissues and cell lines. a, miR-186 expression is markedly decreased in tumor samples
compared to adjacent noncancerous bladder tissues. b The inverse correlation between NSBP1 and miR-186 expression in 20 BC samples
was determined using Spearman’s correlation analysis (r = −0.8946, P <0.05) * P <0.05. c, qRT-PCR analysis revealed the miR-186 expression in human
bladder cancer cell lines (J82, HT1376, RT4, T24 and TCCSUP) and immortalized human bladder epithelium (HCV29) cells. d, Western blot analysis
revealed the NSBP1 expression in human bladder cancer cell lines (J82, HT1376, RT4, T24 and TCCSUP) and immortalized human bladder epithelium
(HCV29) cells. Each bar represents the mean of three independent experiments. * P < 0.01 versus HCV29 cell line
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and TCCSUP) and immortalized human bladder epithe-
lium (HCV29) cells. Consistent with previous studies
[11], the NSBP1 expression was upregulated in all BC
cell lines as compared with that in HCV29 (Fig. 1d).
These data indicates that NSBP1 function as oncogene
in bladder cancer cells.
miR-186 directly targeted NSBP1
In order to elucidate the underlying molecular mechan-
ism, we performed a bioinformatic analysis using mirco-
RNA.org (http://www.microrna.org/microrna/home.do)
to predict the possible target gene of miR-186. We found
that NSBP1 contained theoretical miR-186 binding sites
in its 3′ UTR (Fig. 2a). To further confirm these results,
we constructed luciferase reporter vectors containing
the wild-type (Wt) or mutant (Mut) miR-186 target se-
quences of the NSBP1 3′-UTR (Fig. 2a). Overexpression
of miR-186 significantly inhibited the luciferase activity
of the Wt NSBP1 3′-UTR reporter gene but not the
Mut reporter gene (Fig. 2a).
Next, we transfected NSBP1 siRNAs in J82 cells
(Fig. 2b). Western blot analysis revealed NSBP1 expres-
sion were significantly decreased by NSBP1 siRNA, com-
pared with negative control group (scramble control
siRNA) (P < 0.05). In addition, overexpression of miR-
186 markedly reduced the expression of NSBP1 (Fig. 2b),
but silenced NSBP1 did not affect miR-186 expression.
These results demonstrated that NSBP1 is a direct target
of miR-186 in BC cells (Fig. 2c).
miR-186 regulated BC cell proliferation and invasion by
suppressing NSBP1 expression
To determine the role of NSBP1 and miR-186 in the
bladder cancer cell growth and metastasis, J82 cells were
transiently co-transfected with NSBP1 siRNA (siRNA)
and miR-186 mimic (miR-186). Consistent with the
effects induced by overexpression of miR-186, knock-
down of NSBP1 significantly suppressed the cell viability
(Fig. 3a) and invasion (Fig. 3b and c), whereas overex-
pression of miR-186 did not have further suppressive
effects on cell growth and metastasis in NSBP1-siRNA
-transfected J82 cells.
MiR-186 induces EMT of BC cells by suppressing NSBP1
expression
EMT has been identified as a key role in the invasion
of various cancer cells by the transformation of polar-
ized and adherent epithelial cells into motile and inva-
sive mesenchymal cells. Here, to explore protein
regulated by miR-186 in the EMT process, we investi-
gated the expression of three EMT related proteins, E-
cadherin, N-cadherin and Vimentin by Western blot.
Bladder cancer cells were transfected with NC, miR-
186 mimics, NSBP1 siRNA and co-transfected with
miR-186 mimics and NSBP1 siRNA. Results indicated
the expression of E-cadherin was increased in miR-
186 mimics group compared with NC (Fig. 4a and b).
Moreover, E-cadherin expression in siRNA group was
higher than that in miR-186 group (miR-186 mimics)
and similar with that in miR-186 + siRNA group. N-
cadherin and Vimentin was downregulated signifi-
cantly in miR-186 group (Fig. 4a, c and d). Moreover,
N-cadherin and Vimentin expression in siRNA group
were lower than that in miR-186 group (miR-186
mimics) and similar with that in miR-186 + siRNA
group. This indicated miR-186 represses the expres-
sion of N-cadherin and Vimentin, while promoting the
induction of E-cadherin by targeting NSBP1.
Fig. 2 miR-186 directly targeted NSBP1. a, Sequence alignment of miR-186 and 3′ UTR of NSBP1 using mirco-RNA.org. Luciferase reporter assay
with co-transfection of wild-type or mutant NSBP1 and miR-186 mimics or miR–control (scramble control mimics).in HEK 293 T cells. Error bars
represent ± S.E. and *, p < 0.01 versus negative control (scramble control mimics). b, qRT-PCR analysis revealed the effects of NSBP1 siRNA and
miR-186 mimics on the expression level of miR-186. c, Western blot analysis revealed the effects of NSBP1 siRNA and miR-186 mimics on the
expression level of NSBP1. Error bars represent ± S.E. and *, p < 0.01 versus NC (scramble control siRNA)
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Discussion
NSBP1, also named HMGN5, is a novel member of
HMGN family, which modifies the structure of chroma-
tin to attain a conformation that facilitates and enhances
transcription, histone modifications, replication and re-
pair [5, 6]. Elevated NSBP1 expression is found in a
number of tumors [8, 11], and downregulation of the
NSBP1 gene can inhibit the tumor cell proliferation in
vitro and in vivo [10]. Therefore, NSBP1 inhibition has
recently emerged as a potential target of drug therapy.
Increased NSBP1 expression has been reported in blad-
der cancer tissues and cell lines [11]. However, the
Fig. 3 miR-186 regulates bladder cancer cell proliferation and invasion by suppressing NSBP1 expression. a, Overexpressed miR-186 and silenced
NSBP1 suppressed cell proliferation. Error bars represent ± S.E. and *, p < 0.01 versus NC (scramble control siRNA). b and c, Overexpressed miR-186
and silenced NSBP1 suppressed cell invasion. Error bars represent ± S.E. and *, p < 0.05 versus NC (scramble control siRNA)
Fig. 4 MiR-186 induces EMT of BC cells by suppressing NSBP1 expression. a, Western bolt analysis revealed the effects of miR-186 and NSBP1
on EMT-relative protein expression. b, The effects of miR-186 and NSBP1 on E-cadherin expression. c, The effects of miR-186 and NSBP1 on
N-cadherin expression. d, The effects of miR-186 and NSBP1 on Vimentin expression. Error bars represent ± S.E. and *, p < 0.01 versus NC (scramble
control siRNA). &, p < 0.01 versus miR-186 group
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regulation of NSBP1 by miRNAs in bladder cancer has
not been explored in detail.
In this study, we examined both the regulation of the
NSBP1 pathway by miR-186 in bladder cancer, as well as
its functional significance. The miR-186 has been com-
monly deregulated in various cancers. For example, miR-
186 was reported to be significantly upregulated in most
pancreatic cancer [22]. Recently, miR-186 function as a
tumor suppressive miRNA and miR-186 expression level
is down-regulated in endometrial cancer [23], prostate
cancer [24], medulloblastomas [25], non-small cell lung
carcinoma [26, 27]. However, little is known of its
expression and potential function in bladder cancer.
Here, we report downregulation of miR-186 and demon-
strate its role as a tumor suppressor in bladder cancer.
We observed miR-186 to be downregulated in bladder can-
cer cell lines compared with bladder epithelium (HCV29)
cells. The miRNA target prediction websites www.microR-
NA.org and TargetScan identified the NSBP1 as a possible
target of miR-186. Our results demonstrated that miR-186
directly targets the 3′UTR of NSBP1, as its overexpression
was associated with suppression of luciferase activity in a
reporter plasmid driven by the NSBP1 -3′UTR.
In addition, a significant downregulation of NSBP1
protein levels was observed following miR-186 overex-
pression, indicating the post-transcriptional regulation of
NSBP1 via targeting its 3′UTR. NSBP1 expression is
frequently elevated in a variety of cancers, including
gliomas, prostate cancer and clear cell renal cell carcin-
oma as well as bladder cancer [8–11], and may therefore
represent a promising molecular target for anticancer
therapy. However, there are no reports about specific
miRNAs regulating NSBP1 expression in tumors. NSBP1
has been reported to correlated with the increased
tumor grade and pathologic stage, and lymph node
metastasis in bladder cancer [11], suggesting a role
for NSBP1 in the development and/or progression of
bladder cancer. Our results suggest silencing of miR-
186 as a possible mechanism for NSBP1 overexpres-
sion in bladder cancer.
NSBP1 has been reported to overexpressed in
human bladder cancer tissues compared with para-
neoplastic bladder tissues [11]. Consistent with previ-
ous study, we observed NSBP1 to be overexpressed in
bladder cancer cell lines compared with bladder epi-
thelium (HCV29) cells. Additional studies identified
NSBP1 as a direct functional target of miR-186. miR-
186-mediated suppression of NSBP1 attenuates cell
proliferation and invasion of bladder cancer. So we
speculated that miR-186 function as tumor suppressor
and inhibit bladder cancer proliferation and invasion
by suppressing NSBP1 expression.
EMT, a dynamic and reversible cellular process, is
characterized by loss of cell polarity and intracellular
junctions and acquirement of mesenchymal features,
which contributes to tumor development and metastasis
[29]. Here, we determined the expression of epithelial
marker, E-cadherin, and mesenchymal marker, vimentin
and N-cadherin in bladder cancer cells with altering
expression of miR-186 and NSBP1. Interestingly, we dem-
onstrated that miR-186 mimics and NSBP1 siRNA inhib-
ited EMT and were associated with reduced expression of
E-cadherin and elevated expression of N-cadherin and
vimentin in bladder cancer. Taken together, miR-186
suppress BC cell EMT by targeting NSBP1.
Conclusion
In conclusion, our study demonstrates that miR-186 is sig-
nificantly downregulated in bladder cancer. Ectopic miR-
186 results in suppression of the proliferative, invasive
ability and EMT of bladder cancer by directly targeting
NSBP1. Overall, these studies describe a promising thera-
peutic role for miR-186 in bladder cancer, which appears
to act at least in part by mimicking pharmacological inhib-
itors of NSBP1.
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